天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Molnupiravir

Molnupiravir Struktur
2349386-89-4
CAS-Nr.
2349386-89-4
Englisch Name:
Molnupiravir
Synonyma:
Molnupiravir;EIDD-2801;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;Tube994;Molnupiravir(MK-4482);Molnupiravir(EIDD-2801);IDD-2801;Mopiravir;EIDO-2801
CBNumber:
CB85851964
Summenformel:
C13H19N3O7
Molgewicht:
329.31
MOL-Datei:
2349386-89-4.mol

Molnupiravir Eigenschaften

Schmelzpunkt:
156 - 159°C
storage temp. 
-20°C, Inert atmosphere
L?slichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
Farbe
White to Off-White
InChI
InChI=1/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/s3
InChIKey
HTNPEHXGEKVIHG-JFPRWSRANA-N
SMILES
O[C@@H]1[C@@H]([C@@H](COC(=O)C(C)C)O[C@H]1N1C=C/C(=N/O)/NC1=O)O |&1:1,2,3,12,r|
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H372 Sch?digt bei Hautkontakt und Verschlucken die Organe bei l?ngerer oder wiederholter Exposition. Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" /> P260, P264, P270, P314, P501
Sicherheit
P260 Dampf/Aerosol/Nebel nicht einatmen.
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P314 Bei Unwohlsein ?rztlichen Rat einholen / ?rztliche Hilfe hinzuziehen.
P501 Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Molnupiravir Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment.

History

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-prot biotechnology company wholly owned by Emory University, and with partial funding support from the U.S. government. Since licensed by Ridgeback, all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck.

Definition

Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It derives from a N(4)-hydroxycytidine.
www.ebi.ac.uk

Biologische Aktivit?t

EIDD-2801 is an orally active, 5′-isopropylester prodrug form of the antiviral ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) with known anti-viral activity against SARS-CoV, SARS-CoV-2, RSV, influenza A & B (IAV & IBV), HCV, pestivirus, bovine viral diarrhoea virus (BVDV), Ebola (EBOV), Chikungunya (CHIKV), venezuelan equine encephalitis (VEEV). EIDD-2801 is efficiently hydrolyzed to NHC in vivo, being more orally bioavailable than NHC in nonhuman primates and ferrets, while maintaining similar oral bioavailability as NHC in mice. EIDD-2801 displays in vivo efficacy against pandemic and seasonal IAV strains in ferrets (lowest ED = 2.3 and 7 mg/kg b.i.d. p.o., respectively).

Regulatory Status

Molnupiravir (as EIDD-2801) was developed at Drug Innovation Ventures at Emory (DRIVE), a not-forprofit biotechnology company owned by Emory University, Atlanta. It was then licensed by Ridgeback Biotherapeutics, and is now developed further in cooperation with Merck & Co. (in Europe: Merck Sharp & Dohme/ MSD).
Molnupiravir is not approved by the European Medicines Agency (EMA) or the American Food and Drug Administration (FDA).

Einzelnachweise

[1] Toots M, Yoon J-J, Cox RM et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine 2019;11(515). Epub 23 Oct 2019.
[2] Toots M, Yoon J-J, Hart M et al. . Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model. Transl Res 2020. Epub 2019 Dec 25.
[3] Halford B. An emerging antiviral takes aim at COVID-19. American Chemical Society; 2020 [14.12.2020]; Available from: https://cen.acs.org/pharmaceuticals/drug-development/emergingantiviral-takes-aim-COVID-19/98/web/2020/05.
[4] Ridgeback Biotherapeutics. OVERVIEW OF EIDD-2801 (MK-4482). [Presentation]. provided via email 2020.

Molnupiravir Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Molnupiravir Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 301)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
weifang runzhong fine chemical co., ltd
536-7868377 +8618653686003
sq@runzhongchem.com China 187 58
HangZhou RunYan Pharma Technology Co.,LTD.
+8618882027439
sales2@runyanpharma.com China 302 58
Hubei Yiling biotechnology Co Ltd
+86-18163349544 +86-18163349544
mollylucking@foxmail.com China 2688 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 5857 58
Anhui Ruihan Technology Co., Ltd
+8617756083858
daisy@anhuiruihan.com China 973 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618092446649
sarah@tnjone.com China 1143 58
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32957 60
Jinan Jianfeng Chemical Co., Ltd
0531-88110457; +8615562555968
info@pharmachemm.com China 251 58
Shenzhen Nexconn Pharmatechs Ltd
+86-755-89396905 +86-15013857715
admin@nexconn.com China 10311 58
Shaanxi Dideu Medichem Co. Ltd
18192627656
1012@dideu.com China 3003 58

  • EIDD-2801(EIDD 2801)
  • Uridine, 4-oxime, 5'-(2-methylpropanoate)
  • β-D-N4 hydroxycytidine-5'-isopropyl ester
  • MolnupiravirEIDD-2801(API)
  • UNII-YA84KI1VEW
  • EIDD-2801(Molnupiravir)
  • ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
  • EIDO-2801
  • Molnupiravir-001
  • Molnupiravir (EIDD-2801, MK-4482)
  • Mopiravir
  • MK-4482/EIDD-2801
  • Molnupiravir-001-XA
  • ((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
  • EIDD-2801
  • Tube994
  • Molnupiravir(MK-4482)
  • Molnupiravir(EIDD-2801)
  • ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
  • Horse, wei
  • 13C,15N2]-EIDD-2801
  • Molnupiravir
  • IDD-2801
  • Molunapiravir, API
  • Molnupiravir API
  • Molnupiravir EP Impurity-C
  • Uridine, 4-?oxime, 5'-?(2-?methylpropanoate)
  • Mopinavir
  • 2349386-89-4
  • 234986-89-4
  • chem-chemical
  • 1
  • API
  • 2349386-89-4
Copyright 2019 ? ChemicalBook. All rights reserved